KM Research Hub
← 返回论文库
待处理 入排:符合 图源:待检查 入排置信度 1.00

Phase 3 trial of sequential versus combination treatment in colorectal cancer: The C-cubed study.

Ryo Inada, Takeshi Nagasaka, Mototsugu Shimokawa, Hitoshi Ojima, Shingo Noura, Hiroaki Tanioka, Yoshinori Munemoto, Yasuhiro Shimada, Keiichiro Ishibashi, Yoshiaki Shindo, Hideyuki Mishima, Masasumi Okajima, Yoshiyuki Yamaguchi

Eur J Cancer 169 166-178

PMID35569283
PMCID-
DOI10.1016/j.ejca.2022.04.009
发表日期2022-05-15
入排依据:命中用户提供的消化道肿瘤阳性参考集。
摘要

摘要

BACKGROUND: An optimal treatment strategy using oxaliplatin and bevacizumab for metastatic colorectal cancer has not been defined. We investigated whether the sequential treatment using fluoropyrimidines with bevacizumab followed by the addition of oxaliplatin at first progression was better than a combination treatment using fluoropyrimidines and oxaliplatin with bevacizumab. METHODS: In the sequential treatment, the escalation from fluoropyrimidines plus bevacizumab to fluoropyrimidines plus oxaliplatin with bevacizumab was recommended in case of progressive disease. Time to failure of strategy was the primary end-point, whereas the secondary end-points were overall survival, progression-free survival, overall response rate and safety. RESULTS: Three hundred patients with previously untreated metastatic colorectal cancer were randomised to receive either the sequential treatment (n = 151) or the combination treatment (n = 149). The sequential treatment was superior to the combination treatment about time to failure of strategy (15.2 months; 95% CI, 12.5-17.2 months vs. 7.8 months: 95% CI, 6.3-9.5 months; P < 0.001). However, the median overall survival was 27.5 (95% CI, 24.4 to 32.7) months in the sequential treatment and 27.0 (95% CI, 22.8 to 36.0) months in the combination treatment (hazard ratio, 0.92; 95% CI, 0.66 to 1.28; P = 0.61). The overall response rate was 33.1% in the sequential treatment arm and 51.7% in the combination treatment. CONCLUSIONS: The findings support the extension of the sequential treatment starting from fluoropyrimidine plus bevacizumab to selected patients who do not need an objective response to the threatening disease.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。